Pharmaceutical Preparations · DE · CIK 1503802
Develops and commercializes novel cancer therapies targeting nuclear export for treating cancer and other diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 2, 2026: 7 sold $309K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Paulson Richard A.President and CEO | Sell | 12,361 | $9.41 | $116K |
| Mar 2, 2026 | Poulton StuartEVP, Chief Development Officer | Sell | 5,101 | $9.41 | $48K |
| Mar 2, 2026 | Rangwala ReshmaEVP & Chief Medical Officer | Sell | 5,066 | $9.41 | $48K |
| Mar 2, 2026 | Cheng Sohanya RoshanEVP & Chief Commercial Officer | Sell | 4,604 | $9.41 | $43K |
| Mar 2, 2026 | Mano MichaelEVP, CLO&Secretary | Sell | 3,526 | $9.41 | $33K |
| Mar 2, 2026 | Abate KristinChief Accounting Officer | Sell | 559 | $9.41 | $5K |
| Feb 17, 2026 | Poulton StuartEVP, Chief Development Officer | Sell | 378 | $8.63 | $3K |
| Feb 3, 2026 | Macomber LoriEVP, CFO & Treasurer | Sell | 1,626 | $6.30 | $10K |
| Jan 28, 2026 | Abate KristinChief Accounting Officer | Sell | 50 | $7.03 | $352 |
| Jan 21, 2026 | Abate KristinChief Accounting Officer | Sell | 265 | $5.96 | $2K |
| Oct 1, 2025 | Abate KristinChief Accounting Officer | Sell | 362 | $6.30 | $2K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.